Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - erütematoosne luupus, süsteemne - immunosupressandid - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - ravimid hingamisteede obstruktiivsete haiguste, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastilised ained - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - metformiin vesinikkloriid, saxagliptin, dapagliflozin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - qtrilmet on näidustatud täiskasvanutel vanuses 18 aastat ja vanemad, tüüp 2 diabeet:parandada glycaemic kontrollida, kui metformiin koos või ilma sulphonylurea (su) ja kas saxagliptin või dapagliflozin ei anna adekvaatset kontrolli glycaemic. kui juba ravitakse metformiin ja saxagliptin ja dapagliflozin.

Eesti - eesti - Ravimiamet

astrazeneca gmbh - terbutaliin - süstelahus - 0,5mg 1ml 1ml 10tk

Eesti - eesti - Ravimiamet

astrazeneca gmbh - lidokaiin - nahasprei, lahus - 100mg 1ml 50ml 1tk

Eesti - eesti - Ravimiamet

astrazeneca ab - felodipiin - toimeainet prolongeeritult vabastav tablett - 5mg 90tk; 5mg 20tk; 5mg 14tk; 5mg 98tk; 5mg 500tk; 5mg 28tk; 5mg 50tk; 5mg 30tk

Eesti - eesti - Ravimiamet

astrazeneca ab - felodipiin - toimeainet prolongeeritult vabastav tablett - 10mg 14tk; 10mg 30tk; 10mg 98tk; 10mg 20tk; 10mg 28tk; 10mg 500tk; 10mg 90tk; 10mg 50tk; 10mg 100tk

Eesti - eesti - Ravimiamet

astrazeneca ab - budesoniid - inhalatsioonipulber - 0,2mg 1annus 200annus 1tk; 0,2mg 1annus 100annus 1tk